ROCKVILLE, Md., April 12, 2023 MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization. | April 12, 2023
MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) EVP Thomas M. Ross sold 6,967 shares of the stock in a transaction dated Wednesday, April 5th. The stock was sold at an average price of $5.00, for a total transaction of $34,835.00. The transaction was disclosed in a legal filing with the SEC, which is available through this […]
MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) CEO Douglas Doerfler sold 27,862 shares of the company’s stock in a transaction on Thursday, April 6th. The stock was sold at an average price of $5.03, for a total transaction of $140,145.86. Following the completion of the sale, the chief executive officer now owns 333,197 shares of the […]
MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) CEO Douglas Doerfler sold 7,470 shares of the company’s stock in a transaction that occurred on Tuesday, April 4th. The shares were sold at an average price of $5.03, for a total value of $37,574.10. Following the completion of the transaction, the chief executive officer now directly owns 333,197 […]
MaxCyte, Inc. (LON:MXCT – Get Rating)’s stock price was up 1.3% on Thursday . The stock traded as high as GBX 399.50 ($4.96) and last traded at GBX 395 ($4.91). Approximately 32,114 shares were traded during trading, an increase of 3% from the average daily volume of 31,083 shares. The stock had previously closed at […]